PMID- 33162542
OWN - NLM
STAT- MEDLINE
DCOM- 20210118
LR  - 20210118
IS  - 0485-1439 (Print)
IS  - 0485-1439 (Linking)
VI  - 61
IP  - 9
DP  - 2020
TI  - [Allogeneic hematopoietic stem cell transplantation using posttransplant 
      cyclophosphamide].
PG  - 1402-1410
LID - 10.11406/rinketsu.61.1402 [doi]
AB  - Posttransplant cyclophosphamide (PTCy) was initially developed by the Johns 
      Hopkins group as a graft-versus-host disease (GVHD) prophylaxis for human 
      leukocyte antigen (HLA)-haploidentical stem cell transplantation. Recently, PTCy 
      has been attempted in HLA-matched transplantation. In HLA-haploidentical 
      hematopoietic transplantation, several retrospective studies have compared 
      HLA-matched transplantation with HLA-haploidentical hematopoietic transplantation 
      using PTCy. In these reports, transplantation outcomes have been comparable. 
      Therefore, PTCy- based haploidentical transplantation is a viable alternative to 
      HLA-matched transplantation. Moreover, In HLA-matched transplantation, PTCy alone 
      may be sufficient in the prevention of GVHD in HLA-matched bone marrow 
      transplantation. Although PTCy alone is not enough in HLA-matched peripheral 
      blood stem cell transplantation, PTCy has demonstrated excellent GVHD inhibition 
      when combined with several immunosuppressive agents, such as calcineurin 
      inhibitor and mycophenolate mofetil. Furthermore, PTCy also playing a significant 
      role in other areas, such as aplastic anemia, salvage transplantation for graft 
      failure, and allogeneic transplantation after checkpoint inhibitor use. PTCy can 
      be performed inexpensively and without any special equipment or techniques at any 
      institution. It is expected that PTCy will continue to spread worldwide in the 
      future.
FAU - Sugita, Junichi
AU  - Sugita J
AD  - Department of Hematology, Hokkaido University Faculty of Medicine.
LA  - jpn
PT  - Journal Article
PL  - Japan
TA  - Rinsho Ketsueki
JT  - [Rinsho ketsueki] The Japanese journal of clinical hematology
JID - 2984782R
RN  - 8N3DW7272P (Cyclophosphamide)
SB  - IM
MH  - *Cyclophosphamide/therapeutic use
MH  - *Graft vs Host Disease/prevention & control
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Retrospective Studies
MH  - Transplantation Conditioning
MH  - Transplantation, Haploidentical
OTO - NOTNLM
OT  - Allogeneic hematopoietic stem cell transplantation
OT  - Aplastic anemia
OT  - Check point inhibitor
OT  - Cyclophosphamide
EDAT- 2020/11/10 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/11/09 05:29
PHST- 2020/11/09 05:29 [entrez]
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
AID - 10.11406/rinketsu.61.1402 [doi]
PST - ppublish
SO  - Rinsho Ketsueki. 2020;61(9):1402-1410. doi: 10.11406/rinketsu.61.1402.